166 related articles for article (PubMed ID: 22122820)
1. Simvastatin-induced myopathy with concomitant use of cyclosporine: case report.
Yang WH; Zeng ZS; Ren XW; Li YP; Shang WJ; Feng GW; Zhang LR
Int J Clin Pharmacol Ther; 2011 Dec; 49(12):772-7. PubMed ID: 22122820
[TBL] [Abstract][Full Text] [Related]
2. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Ramsey LB; Johnson SG; Caudle KE; Haidar CE; Voora D; Wilke RA; Maxwell WD; McLeod HL; Krauss RM; Roden DM; Feng Q; Cooper-DeHoff RM; Gong L; Klein TE; Wadelius M; Niemi M
Clin Pharmacol Ther; 2014 Oct; 96(4):423-8. PubMed ID: 24918167
[TBL] [Abstract][Full Text] [Related]
3. SLCO1B1 variants and statin-induced myopathy--a genomewide study.
; Link E; Parish S; Armitage J; Bowman L; Heath S; Matsuda F; Gut I; Lathrop M; Collins R
N Engl J Med; 2008 Aug; 359(8):789-99. PubMed ID: 18650507
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
[TBL] [Abstract][Full Text] [Related]
5. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
Ramakumari N; Indumathi B; Katkam SK; Kutala VK
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
[TBL] [Abstract][Full Text] [Related]
6. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
[TBL] [Abstract][Full Text] [Related]
7. Drug interactions with simvastatin.
Med Lett Drugs Ther; 2008 Oct; 50(1297):83-4. PubMed ID: 18927522
[No Abstract] [Full Text] [Related]
8. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Wilke RA; Ramsey LB; Johnson SG; Maxwell WD; McLeod HL; Voora D; Krauss RM; Roden DM; Feng Q; Cooper-Dehoff RM; Gong L; Klein TE; Wadelius M; Niemi M;
Clin Pharmacol Ther; 2012 Jul; 92(1):112-7. PubMed ID: 22617227
[TBL] [Abstract][Full Text] [Related]
9. Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
Hou Q; Li S; Li L; Li Y; Sun X; Tian H
Medicine (Baltimore); 2015 Sep; 94(37):e1268. PubMed ID: 26376374
[TBL] [Abstract][Full Text] [Related]
10. SLCO1B1 variants and statin-induced myopathy.
Vladutiu GD; Isackson PJ
N Engl J Med; 2009 Jan; 360(3):304. PubMed ID: 19144951
[No Abstract] [Full Text] [Related]
11. The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Voora D; Shah SH; Spasojevic I; Ali S; Reed CR; Salisbury BA; Ginsburg GS
J Am Coll Cardiol; 2009 Oct; 54(17):1609-16. PubMed ID: 19833260
[TBL] [Abstract][Full Text] [Related]
12. The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.
Jiang F; Choi JY; Lee JH; Ryu S; Park ZW; Lee JG; Na HS; Lee SY; Oh WY; Chung MW; Choi SE
Pharmacogenomics; 2017 Apr; 18(5):459-469. PubMed ID: 28350522
[TBL] [Abstract][Full Text] [Related]
13. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
Canestaro WJ; Austin MA; Thummel KE
Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
[TBL] [Abstract][Full Text] [Related]
14. Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.
Luzum JA; Theusch E; Taylor KD; Wang A; Sadee W; Binkley PF; Krauss RM; Medina MW; Kitzmiller JP
J Cardiovasc Pharmacol; 2015 Jul; 66(1):80-5. PubMed ID: 26164721
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition.
Hu M; Mak VW; Tomlinson B
J Clin Pharm Ther; 2011 Jun; 36(3):419-25. PubMed ID: 21545622
[TBL] [Abstract][Full Text] [Related]
16. Clinical Controversy in Transplantation: Tacrolimus Versus Cyclosporine in Statin Drug Interactions.
Migliozzi DR; Asal NJ
Ann Pharmacother; 2020 Feb; 54(2):171-177. PubMed ID: 31441337
[No Abstract] [Full Text] [Related]
17. A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana.
Chan JCM; Ng MH; Wong RSM; Tomlinson B
J Clin Pharm Ther; 2019 Jun; 44(3):381-383. PubMed ID: 30714173
[TBL] [Abstract][Full Text] [Related]
18. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
Xiang Q; Chen SQ; Ma LY; Hu K; Zhang Z; Mu GY; Xie QF; Zhang XD; Cui YM
Pharmacogenomics J; 2018 Dec; 18(6):721-729. PubMed ID: 30250148
[TBL] [Abstract][Full Text] [Related]
19. Researchers worry about myopathy risk for patients taking high-dose simvastatin.
Mitka M
JAMA; 2009 Jan; 301(3):261-2. PubMed ID: 19155447
[No Abstract] [Full Text] [Related]
20. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
Maxa JL; Melton LB; Ogu CC; Sills MN; Limanni A
Ann Pharmacother; 2002 May; 36(5):820-3. PubMed ID: 11978159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]